Phase I-II Trial of Gemcitabine Plus Nab-paclitaxel (GemBrax) Followed by Folfirinox as First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Paclitaxel (Primary) ; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 16 Aug 2017 Planned End Date changed from 1 Mar 2016 to 1 Mar 2020.
- 16 Aug 2017 Planned primary completion date changed from 1 Mar 2015 to 1 Mar 2018.
- 02 Dec 2016 New trial record